A rare chance to reshape the specialty drug landscape
With 70+ biosimilars approved in the U.S. and growing confidence in their clinical effectiveness, we are beginning to see their long-promised benefits come into sharper focus to address some of the most complex and high-cost conditions.
Meet the speakers
Host Johanna Bellon and moderator Meghan Pasicznyk shared key insights from the 2025 Pharmacy in Focus report, “The biosimilar breakthrough in adoption and affordability.” The speakers highlighted strategies to build patient trust and outlined opportunities to partner across the health care ecosystem to unlock value.
Johanna Bellon
Managing Director for Customer and Clinical Analytics, Evernorth Research Institute
Meghan Pasicznyk, PharmD
Vice President, Specialty Product and Strategy Advancement
Pharmacy in Focus: The biosimilar breakthrough
The Evernorth Research Institute’s latest report examines how biosimilars are driving savings for payers and patients while paving the way for a sustainable health care future.
